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1029-195 Does Genetic Polymorphism for Platelet Glycoprotein 
llla Impact Early and Long-Term Outcomes After 
Elective Percutaneous Coronary Interventions? 
POSTER SESSION 
Giora Weisz, Roxana Mehran, Eugenia Nikolsky. Eve D. Aymong, Sotir Polena, lzat 
Hjazi, lssam Moussa, Edward Kreps, Gregg W. Stone, Jeffrey W. Moses, Martin 6. Leon, 
George Dangas, Lenox Hill Hospital Heart and Vascular Institute of New York and 
Cardiovascular Research Foundation, New York, NY 
Background: Genetic polymorphism (PI A2) of the platelet GPllla protein has been 
associated with increased thrombosis and myocardial infarctnon compared to the Al Al 
status; the rare A2A2 status confers the greatest risk, while the AlAZ status confers 
rather modest risk. The association of PI A2 with adverse events after percutaneous cor- 
onary intervention (PCI) is unknown. 
Patients and Methods: We followed 153 consecutive patients with normal baseline CK- 
MB, who underwent elective PCI for symptomatic coronary artery disease for 1 year. All 
patients were tested for PI A2 polymorphism. Adverse events were recorded and adjudi- 
cated by an independent committee blinded to the polymorphism status. All patients 
received ASA and Clopidogrel for one month post PCI. 
Results: The normal (AIAI) and heterozygous (Al AZ) variants were found in 106 
(70.6%) and 45 (29.4%) of the patients respectively; the homozygous variant was not 
detected in this population. Baseline patient and lesion characteristics, as well as platelet 
aggregation assay, maximum activated cloting time value and use of GP Ilb/llla blockers 
were similar between the 2 groups. There were no differences in outcome between 
groups (Table). 
Conclusions: Heterozygous genetic polymorphism PI Al A2 was found in approximately 
one third of patients undergoing elective PCI and it was not associated with any increase 
in early or late adverse outcomes after PCI compared to the normal homozygous PI 
AIAI status. 
AlAl, n=108 AlA2,n=45 p-Value 
Intra-procedural no flowlthrombus 1 (1%) 0 (0%) 1.0 
Any CPK-MB elevation (> normal) 23 (21%) 9 (20%) 0.65 
CPK-MB elevation (r5 X normal) 1 (1%) 2 (4%) 0.21 
MACE at 30-days 4 (3.7%) 0 (0%) 0.32 
MACE at 1 year 6.6% 7.9% 0.72 
1029-196 Diabetics Achieve Lower Activated Clotting Time When 
Given the Same Dose of Heparin as Nondiabetics 
During Percutaneous Coronary Intervention 
Michael S. Lee, Varinder Singh, Salvatore Aametta, Tom Nero, Marshal Fox, James Ft. 
Wile&. St. Luke’s_Roosevelt Hospital Center, New York, NY 
Background: It is well established that adverse clinical outcomes and complications of 
percutaneous coronary intervention (PCI) are more common in diabetics than in non-dia- 
betics. The use of glycoprotein llblllla receptor antagonists has improved clinical out- 
comes. Current PCI guidelines recommend an initial 70 ItJlkg intravenous dose of 
heparin to reach an activated cloning time (ACT) level of 300 to 350 s with the Hemo- 
chrorv8 device. Diabetics may be less sensitive to heparin compared to non-diabetics. 
We hypothesized that an initial heparin dose of 70 IU/kg is not sufficient to adequately 
anticoagulate diabetics undergoing PCI. 
Methods: We retrospectively studied 265 PCI patients treated by intention to receive 70 
IU/kg of unfractionated heparin, and compared initially-achieved ACT in diabetics versus 
non-diabetics. 
Results: Other than the presence or absence of diabetes, there was no statistical differ- 
ence in the baseline characteristics in the two groups. Mean heparin dose given per kg 
was the same in diabetics and non-diabetics (69.1ill.9 vs. 70.2*10.7 IU/kg, p=O.44). 
Achieved initial ACT in the diabetic group was significantly lower than that I” the non-dia- 
betic group (269.5k46.5 vs. 333.6i53.6 s, pcO.001). The results suggest that diabetics 
are less sensitive to unfractionated heparin and have lower ACT levels than non-diabet- 
ics when administered standard weight-dosed heparin. 
Conclusions: Current heparin dosing of 70 IU/kg for PCI leads to suboptimal initial ACT in 
diabetics. Diabetics may need a higher dose of unfractionated heparin to reach optimal 
levels of anticoagulation during PCI. Further investigation is warranted to determine opti- 
mal combinations of antithrombotic and antiplatelet therapies especially in diabetic 
patients. 
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1030-l 78 Sirolimus-Eluting Stent for Treatment of In-Sjtent 
Restenosis: One-Year Angiographic and Intravascular 
Ultrasound Follow-Up 
Kenqo Tanabe. Degertekin Muzaffer, Evelyn Regar, Chi-hang Lee, Pieter C. Smits. 
Willem J. van der Giessen. Pim de Fevter. Jeffrev J. Pooma. Patrick W. Serruvs. 
I .  I  I  
Thoraxcenter, Rotterdam, The Netherlands, Brigham &Women’s Hospital, Boston, MA 
Background: We have previously reported that sirolimus-eluting stems (SES) prevent 
neointimal formation and recurrent restenosis in the treatment of in-stent restenosis (ISR) 
at 4 months after procedure. The aim of this study was to investigate whether the benefi- 
cial effect could be maintained up to 1 year after procedure. 
Methods Patients with severe, recurrent ISR in a native coronary artery and objective 
evidence of ischemia were recruited. They received one or more 16mm sirolimus-eluting 
Bx VELOCITY stems. Quantitative angiographic and 3D IVUS follow-up was performed 
at 4 months and at 1 year. 
Results: A total of 16 patients were recruited including 4 patients with recurrent resteno- 
sis following brachyiherapy aid 1 heart transplant recipient. The average length of the 
restenotic segment was 18.4 f 13.lmm: 3 lesions were focal, 5 diffuse, 5 proliferative 
and 3 total occlusion of the stem. Satisfactory angiographic results were achieved in 15 
out of 16 patients. In one patient who received two SESs in an occluded obtuse marginal 
branch of the circumflex artery. adequate stent expansion could not be achieved despite 
the use of high pressure (24 atm). All patients were discharged without complication 1 
day after the procedure. At 4 month follow-up, 3 patients had anglographic evidence of 
restenosis (1 in-stem and 2 in-lesion) without need for repeat revascularization. The in- 
stent late lumen loss and the volume obstruction of the stem by IVUS was 0.2lmm and 
1.1%. respectively. To date, 3 patients had experienced 4 major adverse cardiac events 
(2 deaths (one sudden death and one heart failure), 1 acute myocardial infarction neces- 
sitating repeat target vessel angioplasty). So far, 7 patients have completed 1 year angio- 
graphic follow-up. The quantitative measurement will be available at the time of 
presentation. 
Conclusion: In this study it will be evaluated whether the beneficial effect of SES in 
patients with severe ISR can be maintained up to 1 year. 
1030-179 Coating of lntracoronary Stents With AC133+ 
Endothelial Progenitor Cells 
Ralf Koester, Markus Guckenbiehl, Ursula Gehling. Sonja Loges, Wulf Ito, Jan Kaehler, 
Dieter Hossfeld. Walter Fiedler. Thomas Meinertz, Thomas Muenzel, University Hospital 
Eppendorf, Hamburg, Germany 
Background: Rapid regeneration of endothekum after coronary stenting reduces resteno- 
sis and thrombosis. Endothelialization may be delayed after treatment with brachyther- 
apy or drug eluting stents. Endothelial progenitor cells (EPC) have a high regenerative 
potential which could enhance reendothelialization at sites of stenting. The aim of these 
experiments was to identify an optimal stent coating for adherence and growth of EPC. 
Methods: ACl33+ EPC were isolated from leukapheresls products. Mononuclear cells 
were isolated by density gradient centrifugation, incubated with AC133-conjugated 
microbeads and processed through a magnetic column. Purified EPC were cultivated in 
IMDM with supplements. 316L steel stents, coated with heparin, alumlnium oxide, 
fibronectin, vitronectin, osteonectin, collagen type I and IV, laminin and uncoated 316L 
steel were incubated with EPC for two weeks. Cell layers were evaluated by microscopy. 
Cell density was scored in 4 categories according to visual assessment of mean cell den- 
slty within three representative microscopic fields and analysis in quadriplets (categories: 
1: O-20; 2: 21-40; 3: 41-60; 4: 61-80 cells/field). 
Results: Within one week of culture EPC became adherent on heparin-, aluminium 
oxide-, fibronectin-, vitronectin-, osteonectin- and collagen-coated stents, whereas there 
was no visible cell attachment to uncoated 316L steel. The highest numbers of cells were 
counted on hepann-. aluminium oxide-, and collagen type IV-coated stents (>41 cells! 
field), whereas cell numbers were significantly lower on collagen type I- and vitronectin- 
coated stents (>21 cells/field). Lowest numbers or no cells were detected on osteonectin- 
, laminin-coated stems and on 316L stents without coating (>O cells/field). Morphological 
features revealed AC133-derived cells grown to confluence as endothelium. 
Conclusions: Endothelial progenitor cells are suitable for coating of coronary stems. 
Stent coating with heparin or aluminium oxide enhances their attachment and growth. 
Stent coating with progenitor cells may offer therapeutic potential in irradiated lesions or 
lesions treated with antiproliferative drugs. 
1030-l 80 The Impact of Sirolimus-Eluting Stents on the Outcome 
of Patients With Bifurcation Lesions 
Kenqo Tanabe, Pedro A. Lemos, Chl-hang Lee, Muzaffer Degertekin, Evelyn Regar, Akis 
C. Aramoatzis. Ron T. van Domburo. Pim de Fetier. Willem J. van der Glessen, Georqe 
Sianos, bieter C. Smits, Paul Cum&s, Arno R;iter. Francesco Saia, Patrick W. _ 
Serruys, Thoraxcenter, Rotterdam, The Netherlands 
Background: Although stents have improved procedural success rate, the treatment of 
bifurcation lesions is still problematic with an increased restenosis rate and need for 
repeat revascularizatin. Sirolimus-eluting stems (SES) have recently proved to virtually 
